Ajinomoto Cambrooke, Inc.
Amber G. is an accomplished professional with extensive experience in product development and account management across various organizations in the food industry. Currently serving as a Senior Product Developer at Ajinomoto Cambrooke, Inc. since May 2023, Amber has held significant roles such as Innovation Manager for Private Brands at Peapod Digital Labs and Key Account Manager at Puratos. Previously, positions included Account Manager III at McCormick & Company and Territory Manager at Tate & Lyle, as well as leadership roles at Stonyfield Farm and Jungbunzlauer. Amber holds dual Bachelor of Science degrees in Food Science and Food Science and Technology from the University of Massachusetts Amherst, earned between 1996 and 2000.
This person is not in any teams
This person is not in any offices
Ajinomoto Cambrooke, Inc.
Ajinomoto Cambrooke, Inc. formerly Cambrooke Therapeutics, Inc. (expansion of Cambrooke Foods) was founded in 2000 by Lynn and David Paolella, the parents of two children diagnosed with a rare disease called phenylketonuria (PKU). PKU is one of the few genetic diseases, which is managed almost entirely with nutritional intervention. The Paolellas’ goal in forming Cambrooke was simple - to develop improved nutritional therapeutic options for those with serious medical disorders. Today, Cambrooke produces medical formulas and foods for the management of a variety of medical conditions and we are continually innovating new nutritional options targeted at a wide array of diseases. Ajinomoto Cambrooke, Inc. - Leaders in Therapeutic Medical Nutrition. Cambrooke was the first medical foods company to launch a natural intact protein for the dietary management of phenylketonuria called Glytactin™ (modified glycomacropeptide). Cambrooke collaborates with academia and industry partners to transform early phase development projects in therapeutic nutrition into viable commercial products. Cambrooke employs scientific experts in the development, manufacturing and commercialization of nutritional therapeutics for patients with rare diseases. Cambrooke’s products are supported by clinical evidence for the nutritional management of medical needs before they are selected for commercialization. Cambrooke believes that both large and small patient populations are important when it comes to complex nutritional requirements.